Coronavirus Update: Gates Foundation To Give $120m For Molnupiravir Access
Executive Summary
The foundation is donating to help supply Merck/Ridgeback’s antiviral to low-income nations; also Pfizer got one step closer to full approval for booster shots of Comirnaty, while the FDA authorized Moderna and J&J boosters, and Daiichi Sankyo made progress on its own mRNA vaccine candidate. Shionogi's once-daily oral antiviral is also moving forward.
You may also be interested in...
Ildong Joins Oral COVID-19 Drug Race Via Shionogi Partnership
Ildong has become the latest Korean pharma firm to start developing an oral COVID-19 drug in the country, potentially competing with Merck and Pfizer’s candidates which are now under approval review locally. The latest co-development deal is also set to expand the market prospects for the antiviral's Japanese originator.
Pfizer’s Bourla On Paxlovid Patent Deal And Why A Similar Approach Won't Work For Comirnaty
Pfizer CEO Albert Bourla discussed the emergency use authorization filing for Paxlovid, expanding access to the COVID-19 pill in lower income countries and booster shots, at the STAT Summit.
Chinese Biotech Bets On Intravenous 3CL Antiviral Contender For COVID-19
While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.